Endoshunt
Lincoln, US · Founded 2022 · 6 employees on LinkedIn · 3 known investors
Find your way into Endoshunt
336 people in our graph share verified history with the Endoshunt team — schools, employers, funds. One of them is your warm intro.
Noubar Afeyanunlockedknows Michael Finn-Henry · together at Massachusetts Institute of Technology (overlapped)
×4knows the team · via Harvard University
×4knows the team · via Massachusetts Institute of Technology
×3knows the team · via Vanderbilt University
EndoShunt develops a catheter-based device to control hemorrhage in traumatic vascular injuries, featuring a length-adjustable occlusion zone, temporary deployment, and an atraumatic tip. The company has functional prototypes validated in benchtop and in vivo studies and is pursuing FDA 510(k) clearance.
Founders & leadership
Endoshunt was founded in 2022 by Michael Finn-Henry.
MF
Michael Finn-HenryinPresident and Co-FounderMichael Finn-Henry has a background in robotics and has worked to advance multiple research projects toward commercialization. He is pursuing a PhD in mechanical engineering at Harvard University under Dr. Conor Walsh and is president and cofounder of EndoShunt Medical, which develops an endovascular device for hemorrhage control in traumatic injuries.
JL
Jeremy LevinNamed on SEC filing
Board
MB
Milad BehbahaniniaMember of Board of Directors
OB
Olivia BuskMember of Board of Directors
Investors · 3
Reported raises · per SEC filings
Form D private placements$75K disclosed across 1 round · 2022
▶$75KraisedNov 2022 · 2 investors · Other Health CareRule 506(b)
▶$75KraisedNov 2022 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jeremy LevinDirector
- Milad BehbahaniniaDirector
- Olivia BuskDirector
- Michael Finn-HenryExecutive Officer, Director
- Offering amount
- $75K
- Amount sold
- $75K
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Endoshunt do?
- EndoShunt develops a catheter-based device to control hemorrhage in traumatic vascular injuries, featuring a length-adjustable occlusion zone, temporary deployment, and an atraumatic tip. The company has functional prototypes validated in benchtop and in vivo studies and is pursuing FDA 510(k) clearance.
- Who founded Endoshunt?
- Endoshunt was founded by Michael Finn-Henry in 2022.
- Who are Endoshunt's investors?
- Endoshunt's investors include New York Angels, Octerra Capital, The Innovation Space.
- How much funding has Endoshunt raised?
- Endoshunt has disclosed $75K raised across 1 round.
- Where is Endoshunt headquartered?
- Endoshunt is headquartered in Lincoln, US.